By Benjamin Horney ( April 13, 2020, 11:40 AM EDT) -- The Blackstone Group on Monday agreed to inject as much as $2 billion into Alnylam Pharmaceuticals Inc. to help the Massachusetts-based biotechnology company advance treatments for cardiovascular and other diseases, in a deal steered by Goodwin Procter, Ropes & Gray and Willkie Farr....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.